TG Therapeutics (TGTX) Misses Q3 EPS by 5c, Beats on Revenues

TG Therapeutics (NASDAQ: TGTX) reported Q3 EPS of ($0.48), $0.05 worse than the analyst estimate of ($0.43). Revenue for the quarter came in at $38.1 thousand versus the consensus estimate of $30 thousand.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Nike names former Pfizer CFO David Denton as new finance chief
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance